Just because people know that a food is nutritious does not mean they will eat it. The new book, "Marketing Nutrition: Soy, Functional Foods, Biotechnology, and Obesity," by Cornell University's Brian Wansink discusses how food marketers, government officials, health professionals and parents can do better. (October 12, 2005)
More than 30 Human Ecology students, staff and faculty have signed on to become Green Ambassadors who will lead a peer-to-peer campaign to conserve campus resources and promote a culture of sustainability across the college.
NEW YORK -- To shut one's eyes was to be transported back to a dark table in a corner of the El Morocco nightclub during the late 1930s. The mournful yet soaring opening of "Rhapsody in Blue," played by jazz virtuoso Al Gallodoro…
Creating community partnerships and developing new techniques to share information are key ways that Cornell and other U.S. universities can help developing countries, says Vice Provost Alice Pell. (May 28, 2009)
Cornell University's expertise in plant and animal diseases has been enlisted in the war on bioterrorism, with funding from the U.S. Department of Agriculture (USDA) program to bolster food and agricultural homeland security protections. Part of the $2.1 million channeled through New York state by the USDA will help establish facilities in both Cornell's College of Agriculture and Life Sciences and College of Veterinary Medicine. The facilities will join a network of laboratories sited strategically throughout the nation to permit rapid and accurate diagnosis of animal-disease threats and to assist states in improving their capabilities to detect plant pests and diseases, according to the USDA announcement of the $43.5 million appropriation to the states. (May 31, 2002)
Students have examined the commercial viability of an emerging business: farming housefly larva meal into animal or fish feed. They are working with faculty fellows at the Atkinson Center for a Sustainable Future.
Three promising and innovative prostate cancer therapies are currently being investigated in clinical trials at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The three trials include separate studies of two monoclonal antibody investigative therapies.
New York, NY (May 20, 2002) Investigators from Weill Medical College of Cornell University today reported encouraging interim results with a new potential therapy for non-Hodgkinâs lymphoma (NHL), which affects about 53,900 new patients each year in the United States. The presentation was made at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, FL.Dr. John P. Leonard, the lead investigator of a trial involving a collaboration of scientists from Weill Cornell, Amgen (of Thousand Oaks, CA), and Immunomedics (of Morris Plains, NJ), reported data from 21 patients who have relapsed and refractory NHLpatients in whom the disease has progressed despite prior treatment. The study is the first trial of a combination of two monoclonal antibodies in lymphomaone of the antibodies a known agent (rituximab) and the other a new one (epratuzumab). Administered together, once weekly for four weeks, the combination has preliminarily shown enhanced efficacy over that which has been previously reported with rituximab alone. Rituximab acts against the CD20 antigen (or target molecule) on NHL cells. Its brand name is Rituxan¨, and it is produced by IDEC, of San Diego, Calif., and Genentech, of San Francisco. Epratuzumab, a new investigational antibody in development by Amgen and Immunomedics, acts against the CD22 antigen of NHL.
At its meetings in New York City Friday, Jan. 21, and Saturday, Jan. 22, the Cornell University Board of Trustees approved a set of planning parameters for the 2005-06 budget that calls for a 4.3 percent tuition increase for most students in the endowed colleges. (January 24, 2005)